Future Elderly Model (FEM)
The Future Elderly Model (FEM) is an economic-demographic microsimulation developed over the last decade by researchers with funding from the Centers for Medicare and Medicaid Services, the National Institute on Aging, the Department of Labor and the MacArthur Foundation. Its development is led by the Schaeffer Center for Health Policy & Economics with collaborators from Harvard…
Study: Exploding Popularity of Ozempic and Wegovy Among Privately Insured Patients May Worsen Disparities
Publicly insured individuals who are most likely to benefit from new diabetes and obesity drugs are less likely to get them than those with private insurance.
A Patient-Focused, Evidence-Driven Approach to PBM Reform
As policymakers consider reforms to the prescription drug supply chain, they should keep five principles in mind to ensure better outcomes for patients.
Value of Life Sciences Innovation
Value of Life Sciences Innovation Steering Committee Co-Chairs Members
Let the Market Determine Drug Prices – Not 19th Century Economics
In health care, the term “value” gets lobbed about quite loosely. It is easy to forget that centuries of economic thought have gone into rigorously examining how worth is determined in a marketplace.
How the Secrecy of Middlemen Inflates Drug Prices
Drug costs can be driven down if market forces are allowed to target those profits, but first everyone needs to know what is being charged, and by whom to whom.
White House Names First 10 Drugs for Medicare Negotiations; USC Policy Experts Available to Discuss Market Impact
Medicare released the list of the first 10 drugs subject to price negotiations under the Inflation Reduction Act (IRA), aiming to reduce drug costs for Medicare enrollees and taxpayers.
Blame Capitalism? Why Hundreds of Decades-Old Yet Vital Drugs Are Nearly Impossible to Find
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Lowering Medicare Advantage Overpayments from Favorable Selection by Reforming Risk Adjustment
One potential path for reducing Medicare Advantage (MA) overpayments from favorable selection is reforming the current administered payment approaches linking spending in fee-for-service (FFS) to MA rates.
Mitigating the Inflation Reduction Act’s Adverse Impacts on the Prescription Drug Market
This paper provides three recommendations to steer the potential effects of the IRA toward its goal of improving patient access while encouraging innovation.
Senate Finance Committee Explores Costly, Secretive Practices in the Drug Supply Chain
Karen Van Nuys testified at the hearing, calling transparency “an essential first step.”
Schaeffer Co-Director Testifies on PBMs at Senate Congressional Hearing
Erin Trish was part of a panel of witnesses called to testify before the Committee on Commerce, Science and Transportation.
Testimony on Bringing Transparency and Accountability to Pharmacy Benefit Managers
Erin Trish spoke at the Senate Committee on Commerce, Science, & Transportation on February 16, 2023 about the complex and influential role that PBMs play in the pharmaceutical distribution system.
Development and Pilot Testing of EHR-Nudges to Reduce Overuse in Older Primary Care Patients
Unnecessary testing and treatment of common conditions in older adults can lead to significant morbidity and mortality.
Drugmakers Aren’t Driving Inflation. Price Controls Would Hinder Medical Progress
Drug prices have not experienced the major rise in cost like eggs or gasoline, and instituting price controls on drugs would only stifle medical innovation.
PBMs Are Inflating the Cost of Generic Drugs. They Must Be Reined In
Anti-competitive practices and a lack of transparency in the generic drug market allow pharmacy benefit managers to profit off patients and payers.
Race and Ethnic Differences in the Association Between Alzheimer’s Disease Risk and Use of Prescription Medications for Chronic Conditions
Schaeffer Center experts analyze the connection between medications for chronic diseases and their impact on Alzheimer’s as well as a lack of representation among racial and ethnic minorities in clinical trials.
2021 Schaeffer Center Annual Report
At the Schaeffer Center, we’ve spent over a decade conducting evidence-based research to ensure access to high-value healthcare, build a healthcare system that is resilient and sustainable, and encourage biomedical innovation that improves quality of life.
USC Schaeffer’s Rocio Ribero Was a Deep Thinker Who Loved Laughter, Her Family and Solving Problems
USC Price is remembering Rocio Ribero, a research scientist who produced groundbreaking work in the Schaeffer Center for Health Policy and Economics.
Top Schaeffer Studies of 2021
Over the past year, Schaeffer Center experts authored over 130 journal articles and 14 white papers. They were also in the media about 5,500 times, including authoring over 40 op-eds and blog posts. Below is a look back at a few of the most impactful studies from 2021.
- ← Previous
- 1
- 2
- 3
- 4
- Next →